March 6, 1991JAMA
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates cost-effectiveness of lovastatin for coronary heart disease prevention, suggesting improved strategies for medication use.
Key Points
- The study aims to assess the cost-effectiveness of HMG-CoA reductase inhibitors for preventing coronary heart disease in different populations.
- Utilized the Coronary Heart Disease Policy Model, a computer-simulated model to assess coronary heart disease incidence and recurrent events.
- Evaluated lovastatin dosages of 20 mg/d and 40 mg/d for secondary prevention in men and women with varying cholesterol levels.
- Compared primary and secondary prevention cost-effectiveness across risk factor profiles.
- 20 mg/d of lovastatin saves lives and costs in younger men with cholesterol levels above 250 mg/dL.
- 40 mg/d of lovastatin shows favorable cost-effectiveness ratios for men with high cholesterol levels.
- Primary prevention shows favorable cost-effectiveness only in select subgroups, suggesting need for tailored recommendations.
Cite This Study
Lee Goldman (1991) studied this question.